
Patient-derived organoids (PDOs) are becoming increasingly valuable translational models for oncology research, providing human-relevant insights into drug response, resistance, and tumor heterogeneity. As oncology drug development becomes more complex, integrating functional screening with molecular and clinical data is essential for more predictive decision-making.
This whitepaper explores how Samsung Organoids combines GxP-aligned patient-derived organoid screening with high-content screening (HCS), multi-omics analysis, and clinical data to generate clinically relevant, data-centric insights that support translational oncology research and drug development.
Key highlights include:
GxP-aligned organoid screening integrated with high-content screening (HCS), multi-omics analysis, and clinical data
Human-relevant translational models for evaluating drug response, resistance, and tumor heterogeneity
Functional drug-response data connected with genomic, transcriptomic, and clinical data
Clinically relevant data delivered through an integrated screening workflow in approximately five weeks
Process development and GMP manufacturing conducted within a single site to support early clinical development
Discover how data-centric organoid services can support more predictive oncology research and accelerate the transition from translational insights to clinical development.

Patient-derived organoids (PDOs) are becoming increasingly valuable translational models for oncology research, providing human-relevant insights into drug response, resistance, and tumor heterogeneity. As oncology drug development becomes more complex, integrating functional screening with molecular and clinical data is essential for more predictive decision-making.
This whitepaper explores how Samsung Organoids combines GxP-aligned patient-derived organoid screening with high-content screening (HCS), multi-omics analysis, and clinical data to generate clinically relevant, data-centric insights that support translational oncology research and drug development.
Key highlights include:
GxP-aligned organoid screening integrated with high-content screening (HCS), multi-omics analysis, and clinical data
Human-relevant translational models for evaluating drug response, resistance, and tumor heterogeneity
Functional drug-response data connected with genomic, transcriptomic, and clinical data
Clinically relevant data delivered through an integrated screening workflow in approximately five weeks
Process development and GMP manufacturing conducted within a single site to support early clinical development
Discover how data-centric organoid services can support more predictive oncology research and accelerate the transition from translational insights to clinical development.